Skip to content
Case File
d-31603House OversightOther

Cannabis Investment Report (December 2017) – Limited investigative value

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024686
Pages
1
Persons
2

Summary

The document is a generic product catalog/marketing sheet for cannabis edibles with no mention of political figures, government agencies, financial transactions, or wrongdoing. It provides no actionab Dated December 2017, produced by Ackrell Capital, LLC (FINRA/SIPC member). Lists various cannabis-infused edible products (chocolate, sparkling water, mints, brownies, gummies Contains branding and d

This document is from the House Oversight Committee Releases.

View Source Collection

Persons Referenced (2)

Tags

product-cataloginvestment-reportcannabisackrell-capitalhouse-oversight
Share
PostReddit

Related Documents (6)

House OversightOtherNov 11, 2025

Ackrell Capital Cannabis Investment Report – Terpene Profile (Dec 2017)

The document is a technical cannabis industry report containing terpene percentages and formulation data. It mentions no high‑profile individuals, government agencies, financial transactions, or contr Provides typical terpene composition percentages for cannabis flower. Describes the concept of the “Entourage Effect” and THC:CBD ratio ranges. Published by Ackrell Capital, a FINRA/SIPC‑registered f

1p
House OversightOtherNov 11, 2025

Ackrell Capital Cannabis Investment Report – Terpene Benefits Overview (Dec 2017)

The passage is a generic industry report describing terpene profiles and alleged medicinal benefits. It contains no references to high‑profile individuals, government agencies, financial transactions, Describes therapeutic claims for various cannabis terpenes (myrcene, pinene, limonene, camphene). Provides a table of purported medical benefits (antianxiety, anti‑inflammatory, etc.). Published by A

1p
House OversightOtherNov 11, 2025

Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017)

The passage is a purely scientific/financial overview of cannabinoid chemistry and investment context. It contains no mention of political figures, government agencies, financial flows tied to powerfu Describes CBDA as a non‑psychoactive precursor to CBD with potential medical benefits. Notes recent cultivation of cannabis strains with high CBDA levels comparable to THC. Explains decarboxylation p

1p
House OversightOtherNov 11, 2025

Cannabis Investment Report – Ackrell Capital (Dec 2017) – Product Overview

The passage is a marketing‑style product description of cannabis flower and concentrates. It contains no references to political figures, government agencies, financial misconduct, or foreign influenc Describes cannabis flower characteristics and typical THC/CBD levels. Lists popular strain names and concentrate types. Claims 100% pesticide‑free product and FINRA/SIPC membership.

1p
House OversightOtherNov 11, 2025

Cannabis Investment Report – Technical Overview of Cannabis Species and Compounds

The passage is a generic scientific and market overview of cannabis biology and does not mention any political figures, government agencies, financial transactions, or misconduct. It offers no actiona Describes three primary cannabis species and hybrid varieties. Explains cannabinoids (THC, CBD) and terpenes and their effects. Details plant anatomy, focusing on trichomes where compounds concentrat

1p
House OversightOtherNov 11, 2025

Ackrell Capital Cannabis Investment Report (Dec 2017) – No substantive investigative leads

The document is a commercial investment report on the cannabis industry with generic market analysis and no mention of specific individuals, transactions, or wrongdoing. It lacks actionable details, n Report outlines cannabis market segments, legal landscape, and forecasts. Contains standard disclosures and acknowledgments from Ackrell Capital, a FINRA/SIPC member. No references to government offi

1p

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.